Business Description
AIM ImmunoTech Inc
NAICS : 325414
SIC : 2836
ISIN : US42366C3016
Description
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.12 | |||||
| Equity-to-Asset | 0.21 | |||||
| Debt-to-Equity | 1.17 | |||||
| Debt-to-EBITDA | -0.13 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -48.81 | |||||
| Beneish M-Score | -5.26 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -7.2 | |||||
| 3-Year EBITDA Growth Rate | -16.9 | |||||
| 3-Year EPS without NRI Growth Rate | -10.1 | |||||
| 3-Year FCF Growth Rate | -9.4 | |||||
| 3-Year Book Growth Rate | -48.7 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 294.71 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 33.45 | |||||
| 9-Day RSI | 34.29 | |||||
| 14-Day RSI | 34.87 | |||||
| 3-1 Month Momentum % | -13 | |||||
| 6-1 Month Momentum % | -46.98 | |||||
| 12-1 Month Momentum % | -54.41 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.75 | |||||
| Quick Ratio | 0.75 | |||||
| Cash Ratio | 0.71 | |||||
| Days Sales Outstanding | 77.8 | |||||
| Days Payable | 55798.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.2 | |||||
| Shareholder Yield % | -35.28 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 81.05 | |||||
| Operating Margin % | -14695.26 | |||||
| Net Margin % | -12594.21 | |||||
| FCF Margin % | -11120 | |||||
| ROE % | -256.33 | |||||
| ROA % | -129.02 | |||||
| ROIC % | -401.15 | |||||
| 3-Year ROIIC % | 87.57 | |||||
| ROC (Joel Greenblatt) % | -3186.64 | |||||
| ROCE % | -261.43 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 30.86 | |||||
| PB Ratio | 2.47 | |||||
| Price-to-Tangible-Book | 12.34 | |||||
| EV-to-EBIT | -0.17 | |||||
| EV-to-EBITDA | -0.17 | |||||
| EV-to-Revenue | 23.45 | |||||
| EV-to-Forward-Revenue | 22.28 | |||||
| EV-to-FCF | -0.21 | |||||
| Price-to-GF-Value | 0.21 | |||||
| Price-to-Median-PS-Value | 0.23 | |||||
| Earnings Yield (Greenblatt) % | -588.24 | |||||
| FCF Yield % | -249.12 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with AMEX:AIM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
AIM ImmunoTech Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.19 | ||
| EPS (TTM) ($) | -0.47 | ||
| Beta | 1.5 | ||
| 3-Year Sharpe Ratio | -0.45 | ||
| 3-Year Sortino Ratio | -0.77 | ||
| Volatility % | 44.49 | ||
| 14-Day RSI | 34.87 | ||
| 14-Day ATR ($) | 0.01933 | ||
| 20-Day SMA ($) | 0.142335 | ||
| 12-1 Month Momentum % | -54.41 | ||
| 52-Week Range ($) | 0.1105 - 0.62 | ||
| Shares Outstanding (Mil) | 68.75 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
AIM ImmunoTech Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
AIM ImmunoTech Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
AIM ImmunoTech Inc Frequently Asked Questions
What is AIM ImmunoTech Inc(AIM)'s stock price today?
The current price of AIM is $0.12. The 52 week high of AIM is $0.62 and 52 week low is $0.11.
When is next earnings date of AIM ImmunoTech Inc(AIM)?
The next earnings date of AIM ImmunoTech Inc(AIM) is 2025-05-16 Est..
Does AIM ImmunoTech Inc(AIM) pay dividends? If so, how much?
AIM ImmunoTech Inc(AIM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers